Blog
RSS FeedPosted by Michael Wonder on 21 May 2022
People dying of COVID while life-saving drugs go unused, doctors say
21 May 2022 - Top doctors have warned that vulnerable patients who test positive to COVID-19 are missing out on ...
Posted by Michael Wonder on 19 Apr 2022
Prioritising reference products over biosimilars led to millions of missed savings for Part D
20 April 2022 - Medicare Part D plans missed out on between $84 million and $143 million in savings by ...
Posted by Michael Wonder on 06 Apr 2022
Some hoped FDA approval of Pfizer's COVID vaccine would convince unvaccinated Americans. It didn't, study finds.
6 April 2022 - After the Food and Drug Administration approved Pfizer-BioNTech’s COVID-19 vaccine in August, public health experts were ...
Posted by Michael Wonder on 25 Mar 2022
DUSC utilisation analysis public release documents
25 March 2022 - The utilisation analysis public release documents from the October 2021 DUSC meeting are now available. ...
Posted by Michael Wonder on 14 Feb 2022
Medscape awarded contract from FDA to develop educational programming focused on biosimilars
14 February 2022 - Medscape Education has been awarded a contract from the U.S. FDA for the development of an ...
Posted by Michael Wonder on 16 Nov 2021
Are we measuring what matters most on uptake to medicines in England?
16 November 2021 - VPAS is a voluntary agreement between the UK government and the Association of the British Pharmaceutical ...
Posted by Michael Wonder on 05 Nov 2021
Drug Utilisation Sub-Committee outcome statement
5 November 2021 - The Outcome Statement from the October 2021 Drug Utilisation SubCommittee meeting is now available. ...
Posted by Michael Wonder on 24 Oct 2021
Patient and payer incentives to use patented brand name drugs vs authorised generic drugs in Medicare Part D
18 October 2021 - This cross-sectional study of Medicare formulary and pricing data for quarter 3 of 2020 found that most ...
Posted by Michael Wonder on 24 Oct 2021
Real world use of and spending on new oral targeted cancer drugs in the US (2011-2018)
18 October 2021 - In this cross-sectional study among 37 348 patients who received 1 or more of 44 new oral targeted ...
Posted by Michael Wonder on 20 Oct 2021
Sales of Biogen’s costly new Alzheimer’s drug fall far short of expectations
20 October 2021 - The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 ...
Posted by Michael Wonder on 08 Oct 2021
Docs ‘use rubber stamp for drugs’
9 October 2021 - Pharmacists have raised the alarm over the influence of a US pharmaceutical corporation on Australian doctors ...
Posted by Michael Wonder on 09 Aug 2021
Barriers to US biosimilar market growth: lessons from biosimilar patent litigation
6 August 2021 - High biologic drug prices have placed substantial strain on the US health care system. ...
Posted by Michael Wonder on 09 Aug 2021
Competition from biosimilars drives price reductions for biologics in the French single payer health system
6 August 2021 - France has a single payer health insurance system that has the authority to impose pharmaceutical price reductions ...
Posted by Michael Wonder on 26 Jul 2021
Full FDA approval is needed to overcome vaccine hesitancy
26 July 2021 - As the Delta variant spreads, what is the agency waiting for? ...
Posted by Michael Wonder on 22 Jul 2021
Biogen sees heavy patient interest in new Alzheimer’s drug
22 July 2021 - Company pushed back against criticism of drug’s effectiveness and approval, saying trial data supported use. ...